oleclumab
talizumab
zanolimumab
elotuzumab
immunoprotective
sonepcizumab
tucotuzumab
intrabody
drozitumab
atezolizumab
durvalumab
ocrelizumab
idiospecific
adebrelimab
antipolyvalent
conatumumab
siltuximab
antimonoclonal
robatumumab
mapatumumab
heteroclitic
afasevikumab
ozoralizumab
antinucleoside
antiplasma
etesevimab
olendalizumab
polyvalent
immunoprotection
teplizumab
adjuvant
dorlixizumab
chromobody
immunoadsorbent
monospecific
polyantibody
panitumumab
pancytokeratin
microlymphocytotoxicity
immunogen
matuzumab
teclistamab
antigenomic
antiantitoxin
agonistic monoclonal antibody
lintuzumab
bispecific
agglutin
presentation
belimumab